You are here

  • Home
  • Online First
  • Blocking LOXL2 and TGFβ1 signalling induces collagen I turnover in precision-cut lung slices derived from patients with idiopathic pulmonary fibrosis

Article Text

Article menu
Download PDFPDF
Brief communication
Blocking LOXL2 and TGFβ1 signalling induces collagen I turnover in precision-cut lung slices derived from patients with idiopathic pulmonary fibrosis
  1. Ying Wei1,
  2. Wenting Dong1,
  3. Julia Jackson2,
  4. Tsung-Che Ho1,
  5. Claude Jourdan Le Saux1,
  6. Alexis Brumwell1,
  7. Xiaopeng Li3,
  8. Julia Klesney-Tait4,
  9. Max L Cohen1,
  10. Paul J Wolters1,
  11. Harold A Chapman1,5
  1. 1Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, California, USA
  2. 2Infectious Disease and Cell Atlas Initiatives, Chan Zuckerberg Biohub, San Francisco, California, USA
  3. 3Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan, USA
  4. 4Internal Medicine, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA
  5. 5Cardiovascular Research Institute, San Francisco, California, USA
  1. Correspondence to Dr Harold A Chapman, Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, California, USA; hal.chapman{at}ucsf.edu; Dr Ying Wei; ying.wei{at}ucsf.edu

Abstract

We recently identified epigallocatechin gallate (EGCG), a trihydroxyphenolic compound, as a dual inhibitor of lysyl oxidase-like2 and transforming growth factor-β1 (TGFβ1) receptor kinase that when given orally to patients with idiopathic pulmonary fibrosis (IPF) reversed profibrotic biomarkers in their diagnostic biopsies. Here, we extend these findings to advanced pulmonary fibrosis using cultured precision-cut lung slices from explants of patients with IPF undergoing transplantation. During these experiments, we were surprised to discover that not only did EGCG attenuate TGFβ1 signalling and new collagen accumulation but also activated matrix metalloproteinase-dependent collagen I turnover, raising the possibility of slow fibrosis resolution with continued treatment.

  • interstitial fibrosis

http://dx.doi.org/10.1136/thoraxjnl-2020-215745

Statistics from Altmetric.com

    View Full Text

    Footnotes

    • YW and HAC are joint senior authors.

    • Contributors YW and HAC made contributions to conception and design of the work and interpretation of data. YW, WD, T-CH, AB, JJ, MLC, and CJLS acquired, analysed and interpreted data. XL, JK-T and PJW provided critical experimental specimens. YW and HAC wrote the manuscript. All authors approved the final version.

    • Funding This work has been funded by Three Lakes Foundation (HAC), NIH R01 HL142265 and R35 HL150767 (HAC) and R21 AG052744 (CJLS).

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.